Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
866 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07203391 | Tebentafusp and Roginolisib in Uveal Melanoma to Prolong T-cell Homeostasis(TRIUMPH) | recruiting | Phase 1 | 8 | St Vincent's Hospital, SydneyOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT06679101 | A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)(DREAMM-10) | recruiting | Phase 3 | 520 | GlaxoSmithKline |
| 24 |
| Apr 22, 2026 |
| clinicaltrials |
| NCT07020221 | A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors | recruiting | Phase 1 / Phase 2 | 295 | Verastem, Inc.INDUSTRY | 2 | Apr 22, 2026 | clinicaltrials |
| NCT06326411 | A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors(NST-628) | recruiting | Phase 1 | 230 | Nested Therapeutics, IncINDUSTRY | 2 | Apr 20, 2026 | clinicaltrials |
| NCT02468024 | JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer(STABLE-MATES) | recruiting | Phase 3 | 272 | University of Texas Southwestern Medical CenterOTHER | 4 | Apr 16, 2026 | clinicaltrials |
| NCT04606446 | Study of PF-07248144 in Advanced or Metastatic Solid Tumors(KAT6) | recruiting | Phase 2 | 320 | PfizerINDUSTRY | 5 | Apr 16, 2026 | clinicaltrials |
| NCT05580562 | ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)(ACTION) | recruiting | Phase 3 | 510 | Jazz PharmaceuticalsINDUSTRY | 18 | Apr 16, 2026 | clinicaltrials |
| NCT06312644 | Study of Ultomiris® (Ravulizumab) Safety in Pregnancy | recruiting | — | 75 | Alexion Pharmaceuticals, Inc.INDUSTRY | 7 | Apr 16, 2026 | clinicaltrials |
| NCT06510699 | Pharmacogenomics for Better Treatment of Fungal Infections Clinical Trial(PRAGMATIC) | recruiting | Phase 2 | 104 | The University of QueenslandOTHER | 2 | Apr 16, 2026 | clinicaltrials |
| NCT05718895 | A Study of ATG-022 in Patients With Advanced/Metastatic Solid Tumors(CLINCH) | recruiting | Phase 1 | 156 | Antengene Biologics LimitedINDUSTRY | 2 | Apr 15, 2026 | clinicaltrials |
| NCT04686305 | Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC(DL03) | recruiting | Phase 1 | 304 | AstraZenecaINDUSTRY | 19 | Apr 13, 2026 | clinicaltrials |
| NCT06960395 | Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 450 | Vir Biotechnology, Inc.INDUSTRY | 2 | Apr 13, 2026 | clinicaltrials |
| NCT06064877 | A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma(FIERCE-HN) | recruiting | Phase 3 | 410 | AVEO Pharmaceuticals, Inc.INDUSTRY | 18 | Apr 9, 2026 | clinicaltrials |
| NCT06067347 | A Global Study of the PETAL Consortium(PETAL) | recruiting | — | 1,200 | Massachusetts General HospitalOTHER | 4 | Apr 9, 2026 | clinicaltrials |
| NCT05286788 | MEKTOVI® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma | recruiting | Phase 2 | 38 | Nationwide Children's HospitalOTHER | 3 | Apr 8, 2026 | clinicaltrials |
| NCT04516447 | A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer(MUIR) | recruiting | Phase 1 | 172 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, IncINDUSTRY | 7 | Apr 7, 2026 | clinicaltrials |
| NCT05203172 | The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials | recruiting | Phase 4 | 46 | PfizerINDUSTRY | 17 | Apr 7, 2026 | clinicaltrials |
| NCT04294927 | TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention(TUBA-WISP-II) | recruiting | N/A | 3,000 | University Medical Center NijmegenOTHER | 16 | Apr 6, 2026 | clinicaltrials |
| NCT04665206 | Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 434 | Vivace Therapeutics, IncINDUSTRY | 2 | Apr 2, 2026 | clinicaltrials |
| NCT06351631 | A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017) | recruiting | Phase 3 | 400 | Merck Sharp & Dohme LLCINDUSTRY | 6 | Apr 2, 2026 | clinicaltrials |
| NCT06581406 | A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma | recruiting | Phase 2 / Phase 3 | 280 | Replimune, Inc.INDUSTRY | 3 | Apr 2, 2026 | clinicaltrials |
| NCT05304377 | A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia(CML) | recruiting | Phase 1 | 250 | Enliven TherapeuticsINDUSTRY | 14 | Apr 1, 2026 | clinicaltrials |
| NCT05735080 | Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer(INX-315-01) | recruiting | Phase 1 / Phase 2 | 150 | Incyclix BioINDUSTRY | 2 | Apr 1, 2026 | clinicaltrials |
| NCT05862012 | Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1) | recruiting | Phase 1 | 200 | Ichnos Sciences SAINDUSTRY | 7 | Apr 1, 2026 | clinicaltrials |
| NCT07197580 | Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC(LUTEON) | recruiting | Phase 3 | 40 | Telix Pharmaceuticals (Innovations) Pty LimitedINDUSTRY | 1 | Apr 1, 2026 | clinicaltrials |
| NCT07259213 | A Study of Terbium 161 (161Tb)-RAD402 in Participants With CRPC(RAD402) | recruiting | Phase 1 / Phase 2 | 73 | Radiopharm Theranostics, LtdINDUSTRY | 1 | Apr 1, 2026 | clinicaltrials |
| NCT06770569 | A Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HRS-3802 Monotherapy in Patients With Malignant Solid Tumors | recruiting | Phase 1 | 100 | Shandong Suncadia Medicine Co., Ltd.INDUSTRY | 2 | Mar 30, 2026 | clinicaltrials |
| NCT05756322 | The Safety and Tolerability of LBS-007 in Patients With Relapsed or Resistant Acute Leukaemias | recruiting | Phase 1 / Phase 2 | 90 | Lin BioScience, IncINDUSTRY | 4 | Mar 27, 2026 | clinicaltrials |
| NCT05427487 | Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours | recruiting | Phase 1 | 70 | ImmVirx Pty LtdINDUSTRY | 1 | Mar 25, 2026 | clinicaltrials |
| NCT06630806 | A Study to Investigate the Safety and Efficacy of SAR446523 Injected Subcutaneously in Adult Participants With Relapsed/Refractory Myeloma | recruiting | Phase 1 | 87 | SanofiINDUSTRY | 7 | Mar 25, 2026 | clinicaltrials |
| NCT06932562 | A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant | recruiting | Phase 3 | 1,000 | European Myeloma Network B.V.NETWORK | 18 | Mar 25, 2026 | clinicaltrials |
| NCT07478952 | A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189 in Healthy Adults 18 to 30 Years of Age | recruiting | Phase 1 | 120 | ModernaTX, Inc.INDUSTRY | 1 | Mar 24, 2026 | clinicaltrials |
| NCT07491081 | EARLY Study: Evaluating the Specificity and Feasibility of the EARLY Biomarker Panel for Ovarian Cancer Detection | recruiting | N/A | 1,500 | Queensland Centre for Gynaecological CancerOTHER_GOV | 1 | Mar 24, 2026 | clinicaltrials |
| NCT07222969 | A Clinical Study to Evaluate the Safety of VIB305 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 146 | Vibrant Sciences LimitedINDUSTRY | 2 | Mar 23, 2026 | clinicaltrials |
| NCT04655404 | A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion | recruiting | Early Phase 1 | 15 | Nationwide Children's HospitalOTHER | 5 | Mar 18, 2026 | clinicaltrials |
| NCT05636514 | Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDS(CELESTIAL-MDS) | recruiting | Phase 1 | 12 | Clinical Hub for Interventional Research (CHOIR)OTHER_GOV | 1 | Mar 18, 2026 | clinicaltrials |
| NCT06244771 | A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors(PROSPER) | recruiting | Phase 1 / Phase 2 | 403 | Frontier Medicines CorporationINDUSTRY | 3 | Mar 18, 2026 | clinicaltrials |
| NCT06804824 | A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 220 | Vividion Therapeutics, Inc.INDUSTRY | 2 | Mar 18, 2026 | clinicaltrials |
| NCT03590171 | International Study for Treatment of High Risk Childhood Relapsed ALL 2010 | recruiting | Phase 2 | 250 | Charite University, Berlin, GermanyOTHER | 15 | Mar 17, 2026 | clinicaltrials |
| NCT06926075 | Early Phase Study of KESONOTIDE™in Participants With Solid Tumours(ADVICE) | recruiting | Phase 1 / Phase 2 | 80 | Filamon LTDINDUSTRY | 1 | Mar 17, 2026 | clinicaltrials |
| NCT06736704 | SNV4818 in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 320 | Pikavation Therapeutics, Inc.INDUSTRY | 3 | Mar 13, 2026 | clinicaltrials |
| NCT04075305 | The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study(MOMENTUM) | recruiting | — | 8,000 | UMC UtrechtOTHER | 9 | Mar 5, 2026 | clinicaltrials |
| NCT07110584 | Dose Escalation and Dose Expansion Study of MDX2004 in Participants With Advanced Tumors | recruiting | Phase 1 / Phase 2 | 235 | ModeX Therapeutics, An OPKO Health CompanyINDUSTRY | 2 | Mar 5, 2026 | clinicaltrials |
| NCT07122258 | Early Feasibility Study (EFS) of the 'CAROL' for Treatment of Lung Cancer Stage 1 | recruiting | N/A | 7 | Tau Medical Australia Pty LtdINDUSTRY | 1 | Mar 5, 2026 | clinicaltrials |
| NCT07072728 | Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder | recruiting | Phase 2 | 87 | Psyence Australia Pty LtdINDUSTRY | 1 | Mar 3, 2026 | clinicaltrials |
| NCT06876649 | A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib | recruiting | Phase 4 | 787 | Eli Lilly and CompanyINDUSTRY | 8 | Mar 2, 2026 | clinicaltrials |
| NCT06876662 | A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma | recruiting | Phase 4 | 279 | Eli Lilly and CompanyINDUSTRY | 8 | Mar 2, 2026 | clinicaltrials |
| NCT06956690 | A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors | recruiting | Phase 1 / Phase 2 | 180 | Hummingbird BioscienceINDUSTRY | 2 | Mar 2, 2026 | clinicaltrials |
| NCT07064122 | A Study of AZD2962, an IRAK4 Inhibitor (IRAK4 [a Body Protein] Blocker), in Participants With Haematologic Neoplasms (Blood Cancers) | recruiting | Phase 1 | 72 | AstraZenecaINDUSTRY | 7 | Mar 2, 2026 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials